TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12667970

Group type: EXPERIMENTAL
Intervention: Needling LI4 with manipulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Needling LI4 without manipulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Needling nonacupoint with manipulation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Needling nonacupoint without manipulation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Inactive laser to LI4
Number of subjects: 13
Study: 11334653

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959
Study: 9426377

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD, 120 mg p.o., 60 min before OGTT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral glucose load (OGTT, 100 g p.o. at 0 min) alone
Number of subjects: 16
Study: 8179648

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study: 3432378

Group type: EXPERIMENTAL
Intervention: Photopic luminance sensitivity
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Scotopic luminance sensitivity
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral temperatures
Number of subjects: 3
Study: 2403908

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily before breakfast
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 31116913

Group type: EXPERIMENTAL
Intervention: IVUS-guided drug-eluting stent (DES) implantation
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Angiography-guided drug-eluting stent (DES) implantation
Number of subjects: 1443
Study: 28490648

Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg twice daily
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg twice daily
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg twice daily
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg once daily (active control)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study: 25485880

Group type: EXPERIMENTAL
Intervention: Acetaminophen, meloxicam and gabapentin (AMG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen and meloxicam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen and gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meloxicam and gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All four analgesic regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cough-evoked pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain at rest, during sitting and peak expiration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak expiratory flow rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timed up and go test (TUG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Brief Pain Inventory (mBPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain and TUG correlation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain and activity interference correlation
Number of subjects: 0
Study: 23246175

Group type: EXPERIMENTAL
Intervention: Fortified corn‐soy blended flour (CSB++)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Soy ready‐to‐use supplementary food (RUSF)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Soy/whey ready‐to‐use supplementary food (RUSF)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Refusing food
Number of subjects: 409
Study: 20825879

Group type: EXPERIMENTAL
Intervention: Balanced electrolyte solution (BES)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 45
Study: 19950733

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhalational anesthesia with 1 MAC sevoflurane
Number of subjects: 60
Study: 17937086

Group type: EXPERIMENTAL
Intervention: 50 IU/kg of tinzaparin sodium daily (Group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 100 mg of aspirin daily (Group B)
Number of subjects: 62
Study: 14624187

Group type: EXPERIMENTAL
Intervention: Venlafaxine (300 mg/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Paroxetine (60 mg/d)
Number of subjects: 150
Study: 10532607

Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis (LVL)
Number of subjects: 41
Study: 8610735

Group type: EXPERIMENTAL
Intervention: MRI with intravenous gadolinium contrast and manual mixing of the diffused contrast
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lateral approach for knee arthrocentesis
Number of subjects: 5
Study: 1744486

Group type: EXPERIMENTAL
Intervention: Local cooling of the nailfold capillaries in patients with Crohn's disease
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravital microscopy of nailfold capillaries in patients with Crohn's disease
Number of subjects: 35
Study: 6339029

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 31914971

Group type: EXPERIMENTAL
Intervention: Electronic brief intervention to reduce alcohol misuse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time-and attention-matched control
Number of subjects: 0
Study: 31355323

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg weekly
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg weekly
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg weekly (after relapse on 0.2 g/kg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg weekly (after dose reduction from 0.4 g/kg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 82
Study: 28148629

Group type: EXPERIMENTAL
Intervention: PR fampridine (open-label)
Number of subjects: 53

Group type: COMPARATOR
Intervention: PR fampridine (double-blind controlled)
Number of subjects: 53
Study: 25454965

Group type: EXPERIMENTAL
Intervention: Student-led (SL) group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Instructor-led group
Number of subjects: 12
Study: 23838107

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Early Revascularization
Number of subjects: 1148
Study: 21270384

Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFA supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: n‐6 PUFAs
Number of subjects: 22
Study: 19811112

Group type: EXPERIMENTAL
Intervention: EFF1009 (medical food emulsion)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (emulsion)
Number of subjects: 21
Study: 16293341

Group type: EXPERIMENTAL
Intervention: MELANOTAN (NDP‐MSH)
Number of subjects: 77
Study: 15201244

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 10623701

Group type: EXPERIMENTAL
Intervention: Oral fenretinide 200 mg/d for 28 days before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo pills for 28 days before surgery
Number of subjects: 30
Study: 9186211

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no hemodilution)
Number of subjects: 33
Study: 1364188

Group type: EXPERIMENTAL
Intervention: Enteral nutrition via fine-needle catheter jejunostomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 12
Study: 3966742

Group type: EXPERIMENTAL
Intervention: Continuous oxygen therapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Nocturnal oxygen therapy
Number of subjects: 203
Study: 31690831

Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine (lapatinib 1000 mg daily; vinorelbine 20 mg/m2 D1, D8 q3w)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2 D1, D8 q3w)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine
Number of subjects: 149

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 149
Study: 29956458

Group type: EXPERIMENTAL
Intervention: Nutrition-specific and nutrition-sensitive interventions
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Maternal morbidity
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Perceptions of ideal diet during pregnancy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Awareness of optimal foods for supporting healthy pregnancies
Number of subjects: 153
Study: 28713059

Group type: EXPERIMENTAL
Intervention: Fox's single pentagon technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Modified Crawford double triangle technique
Number of subjects: 50
Study: 25088067

Group type: EXPERIMENTAL
Intervention: Extrafine BDP/FF NEXThaler(®) 100/6 μg bid
Number of subjects: 754

Group type: COMPARATOR
Intervention: Extrafine BDP/FF pMDI 100/6 μg bid
Number of subjects: 754

Group type: COMPARATOR
Intervention: Non-extrafine BDP DPI 100 μg bid
Number of subjects: 754
Study: 23123362

Group type: EXPERIMENTAL
Intervention: Placebo effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 0
Study: 21037469

Group type: EXPERIMENTAL
Intervention: Norepinephrine-dobutamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 30
Study: 19115650

Group type: EXPERIMENTAL
Intervention: 0.15% levobupivacaine (3.3 ml bolus on demand, 5 mg/hour background infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% levobupivacaine (1 ml bolus on demand, 5 mg/hour background infusion)
Number of subjects: 60
Study: 16804151

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg each night)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 46
Study: 14585898

Group type: EXPERIMENTAL
Intervention: 3.3 mm mini-hysteroscope (group B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 5 mm traditional hysteroscope (group A)
Number of subjects: 200
Study: 10903050

Group type: EXPERIMENTAL
Intervention: Cervical epidural morphine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Thoracic epidural morphine
Number of subjects: 29
Study: 9294496

Group type: EXPERIMENTAL
Intervention: Bromocriptine (D2 receptor agonist)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8375125

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine once daily
Number of subjects: 12
Study: 3760403

Group type: EXPERIMENTAL
Intervention: Potassium metabisulfite (K2S2O5, 1 mg/ml) skin testing
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single‐blind oral provocative challenge tests with K2S2O5 (1, 5, 10, 25, and 50 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 53
Study: 30291414

Group type: EXPERIMENTAL
Intervention: Trans-muscular approach (TQL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intra-muscular approach (IQL)
Number of subjects: 54
Study: 27242201

Group type: EXPERIMENTAL
Intervention: Lateral asymmetric decubitus posture
Number of subjects: 322

Group type: COMPARATOR
Intervention: Dorsal recumbent posture (Control)
Number of subjects: 322
Study: 24616448

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride 1,500 mg in beverage form
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 201
Study: 23739654

Group type: EXPERIMENTAL
Intervention: 2×‐RDA (1.6 g kg(‐1) d(‐1))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3×‐RDA (2.4 g kg(‐1) d(‐1))
Number of subjects: 39

Group type: COMPARATOR
Intervention: RDA (0.8 g kg(‐1) d(‐1))
Number of subjects: 39
Study: 20714273

Group type: EXPERIMENTAL
Intervention: Home-based VCT
Number of subjects: 7184

Group type: COMPARATOR
Intervention: Clinic-based VCT
Number of subjects: 7184
Study: 18422711

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) treatment, 5% sodium fluoride, applied twice per year
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Control group (no varnish)
Number of subjects: 1275
Study: 17120841

Group type: EXPERIMENTAL
Intervention: Increasing spatial frequency of elements in the intersection area up to 10 cycles deg(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition from perceiving distinct colors to a perceptually uniform grey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of transparency with color discrimination
Number of subjects: 0
Study: 12820852

Group type: EXPERIMENTAL
Intervention: DenOptix
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: DigiDent
Number of subjects: 433

Group type: COMPARATOR
Intervention: Digora
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Dimax2
Number of subjects: 433

Group type: COMPARATOR
Intervention: Orthophos Plus
Number of subjects: 433
Study: 10795775

Group type: EXPERIMENTAL
Intervention: 3 months of exercise intervention
Number of subjects: 125
Study: 7867240

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day (increased to 100 mg/day based on response)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Diltiazem-SR 90 mg b.i.d. (increased to 180 mg b.i.d. based on response)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 2766902

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 23

Group type: COMPARATOR
Intervention: No enteric-coated aspirin
Number of subjects: 23
Study: 23793

Group type: EXPERIMENTAL
Intervention: Camazepam 30 mg per day for 20 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31761418

Group type: EXPERIMENTAL
Intervention: Intensive intervention group (IG, n=75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional group (CG, n=75)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensive intervention group (IG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 150
Study: 30442714

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg administered subcutaneously every 2 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously every 2 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 27925657

Group type: EXPERIMENTAL
Intervention: 1g cefazolin
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 2g cefazolin
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 3g cefazolin
Number of subjects: 67
Study: 26573454

Group type: EXPERIMENTAL
Intervention: Quince syrup (0.6 cc/kg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Omeprazole (1 cc/kg/day)
Number of subjects: 80
Study: 23949147

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 108
Study: 21922528

Group type: EXPERIMENTAL
Intervention: Palifermin (KGF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palifermin (low dose 240μg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palifermin (day 30 ALC >600 ×106/L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18192900

Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine daily for 54 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 110
Study: 16494645

Group type: EXPERIMENTAL
Intervention: diclofenac potassium sachets (50 mg)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: diclofenac potassium tablets (50 mg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 184
Study: 14664680

Group type: EXPERIMENTAL
Intervention: New metrically comparable effect-size measures and estimators for multifactor designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variance-preservation model and variance-reduction model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical test for checking the validity of model assumptions
Number of subjects: 0
Study: 10784227

Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg daily for 7 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Comparison of Quinapril vs Placebo
Number of subjects: 7
Study: 26630717

Group type: EXPERIMENTAL
Intervention: Dentrust toothbrush
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oral-B P35 toothbrush
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 57
Study: 8466097

Group type: EXPERIMENTAL
Intervention: Salmeterol 12.5 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms
Number of subjects: 24

Group type: COMPARATOR
Intervention: Albuterol 200 micrograms
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3485071

Group type: EXPERIMENTAL
Intervention: Lactate-gel (pH 3.5, 5 ml) inserted into the vagina daily for 7 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Oral metronidazole, 500 mg twice daily for 7 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both lactate-gel and metronidazole
Number of subjects: 62
Study: 30982368

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy pregnant women)
Number of subjects: 80
Study: 29055611

Group type: EXPERIMENTAL
Intervention: Mobile mammographic services
Number of subjects: 538

Group type: COMPARATOR
Intervention: Fixed facility
Number of subjects: 538
Study: 27189020

Group type: EXPERIMENTAL
Intervention: Web-based multimedia decision aid
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 261
Study: 24675287

Group type: EXPERIMENTAL
Intervention: Tamoxifen 30mg daily for one year
Number of subjects: 1716

Group type: EXPERIMENTAL
Intervention: Tamoxifen in luminal A subtype
Number of subjects: 1716

Group type: EXPERIMENTAL
Intervention: Tamoxifen in luminal B/HER2- subtype
Number of subjects: 1716

Group type: EXPERIMENTAL
Intervention: Tamoxifen in luminal A and B subtypes
Number of subjects: 1716
Study: 22499461

Group type: EXPERIMENTAL
Intervention: Home-based intervention program supervised by home helpers, including a self-administered exercise program and 10 g amino-acid supplementation.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Home-based intervention program supervised by home helpers.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Home-based intervention program supervised by home helpers (good compliers).
Number of subjects: 102
Study: 20306357

Group type: EXPERIMENTAL
Intervention: High-level warning group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low-level warning group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Unwarned simulator group
Number of subjects: 78
Study: 18634944

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 22
Study: 15623360

Group type: EXPERIMENTAL
Intervention: Tendo‐Achilles lengthening (TAL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Total‐contact casting (TCC)
Number of subjects: 29
Study: 12047483

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg single dose on day 1 followed by 62.5 mg twice daily for 5.5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 5.5 days plus ketoconazole 200 mg once daily for 6 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (Bosentan only)
Number of subjects: 10
Study: 10068176

Group type: EXPERIMENTAL
Intervention: 200 microg OTFC
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 400 microg OTFC
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: OTFC (various doses: 200, 400, 600, 800, 1200, 1600 microg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: OTFC
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual rescue drug
Number of subjects: 74
Study: 7783098

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (ISH) defined as SBP >= 160 mmHg and DBP < 90 mmHg
Number of subjects: 6621

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (ISH)
Number of subjects: 6621
Study: 1792612

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Propranolol (PP)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Prazosin (PS)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 419
Study: 6362559

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 88
Study: 31278011

Group type: EXPERIMENTAL
Intervention: Working memory training during the postoperative period
Number of subjects: 34

Group type: COMPARATOR
Intervention: Active control group engaging in alternative activities
Number of subjects: 34
Study: 29566379

Group type: EXPERIMENTAL
Intervention: Apabetalone 100mg twice-daily for 24 and 26 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26914983

Group type: EXPERIMENTAL
Intervention: SMART criteria
Number of subjects: 251

Group type: COMPARATOR
Intervention: WHO criteria
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 251
Study: 25371578

Group type: EXPERIMENTAL
Intervention: Connective Tissue Mobilization (CTM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 22496334

Group type: EXPERIMENTAL
Intervention: Eversion carotid endarterectomy (CEA)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Conventional carotid endarterectomy (CEA)
Number of subjects: 563
Study: 20347259

Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19